Stoke Therapeutics, Inc. 8-K

What Happened
Stoke Therapeutics, Inc. filed an 8-K on June 4, 2026 reporting results from its June 3, 2026 Annual Meeting of Stockholders. Three Class I directors — G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D., and Julie Anne Smith — were elected to three-year terms (expiring at the 2029 annual meeting or until their successors qualify). The company’s appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal 2026 was ratified. The company also held a non-binding advisory (say-on-pay) vote on executive compensation, which was approved.

Key Details

• Director elections (votes for / withheld / broker non-votes):
  • G. Clare Kahn, Ph.D.: 49,722,339 For; 308,644 Withheld; 5,143,930 Broker Non-Votes
  • Adrian Krainer, Ph.D.: 36,531,612 For; 13,499,371 Withheld; 5,143,930 Broker Non-Votes
  • Julie Anne Smith: 43,500,649 For; 6,530,334 Withheld; 5,143,930 Broker Non-Votes
• Auditor ratification: Ernst & Young LLP ratified with 55,121,163 For; 2,036 Against; 51,714 Abstaining.
• Say-on-pay (advisory): 36,436,275 For; 13,565,293 Against; 29,415 Withheld/Abstaining; 5,143,930 Broker Non-Votes.

Why It Matters
Director elections determine the board overseeing company strategy and governance through 2029; investors track board composition for oversight of programs and management. Ratifying Ernst & Young preserves auditor continuity for the 2026 financial year. The non-binding say-on-pay vote passed by a majority but with notable opposition (about 13.6M votes against), which investors may view as a signal to monitor executive compensation practices and future governance engagement.